Home > Neurology > EAN 2020 > Multiple Sclerosis > Fampridine treatment results in routine clinical practice

Fampridine treatment results in routine clinical practice

Presented By
Dr Giovanni Castelnovo, Centre Hospitalier Régional Universitaire de Nîmes, France
Conference
EAN 2020
Trial
LIBERATE
Long-term treatment with prolonged-release fampridine (PR-FAM) in the LIBERATE study showed clinical benefits consistent with those previously reported [1]. No new safety signals were identified in this real-world study, suggesting that routine risk minimisation measures were effective. PR-FAM 10 mg twice-daily is indicated for the improvement of walking in adult multiple sclerosis (MS) patients with walking disability (Expanded Disability Status Scale [EDSS] 4-7). The observational LIBERATE study recruited patients newly prescribed PR-FAM at 201 sites in 13 countries. MS Impact Scale-29 (MSIS-29) physical impact score improved significantly for patients on-treatment for 12 months versus those who discontinued (mean change from baseline to 12 months: 9.99 vs -0.34 points; P<0.001). Results were similar for MSIS...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on